Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05441943 | Lymphaticovenous Anastomosis as Treatment for Lymphedema | active not recruiting | N/A | 10 | Odense University HospitalOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06286267 | AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors | recruiting | — | 4,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05698056 | A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence(ODELIA) | active not recruiting | — | 25,000 | Technische Universität DresdenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06195371 | Impact of CASP3 Gene in Chemoresistance | not yet recruiting | — | 60 | Gehad Salah El-Din shakerOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06270355 | Stockholm Mammography Risk Stratified Trial(SMART) | not yet recruiting | Phase 3 | 70,000 | Karolinska InstitutetOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06281145 | Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer(SRI-BrCa_CRC) | recruiting | N/A | 100 | Comenius UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281210 | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery(BETTY-CRASY) | recruiting | N/A | 77 | European Institute of OncologyOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06282796 | Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy | recruiting | — | 600 | First Hospital of China Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06234150 | Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment(ADANC) | not yet recruiting | N/A | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06266026 | ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography.(ThermoBreast) | recruiting | N/A | 28,000 | ThermoMind Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06268652 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | recruiting | Phase 3 | 302 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06259162 | LAG3 Expression in Triple Negative Breast Cancer | recruiting | N/A | 128 | Samsung Medical CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06259513 | Omission of Axillary Surgery in Breast Cancer Patients | recruiting | N/A | 350 | KK Women's and Children's HospitalOTHER_GOV | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06254690 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | recruiting | Phase 2 | 102 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05949541 | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer(BCTOP-L-M01) | recruiting | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02839863 | Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The UMBRELLA Cohort(UMBRELLA) | recruiting | — | 10,000 | UMC UtrechtOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | recruiting | Phase 3 | 372 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06235931 | A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC | recruiting | N/A | 34 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06169072 | Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients(MagSnow2) | recruiting | Phase 2 | 220 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06131632 | Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy(ConSIBreC) | not yet recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02965950 | The p53 Breast Cancer Trial(p53b) | active not recruiting | Phase 2 | 190 | Haukeland University HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05993559 | Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy | not yet recruiting | Phase 3 | 1,314 | Gangnam Severance HospitalOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT01717131 | Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node | active not recruiting | N/A | 2,228 | Institut Paoli-CalmettesOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06162559 | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study(TRAIN-4) | recruiting | Phase 1 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06202313 | Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 128 | Shengjing HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06193122 | Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment | not yet recruiting | — | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06193707 | Intelligent Remote Intervention for High-risk Breast Cancer Populations | not yet recruiting | N/A | 1,250 | Qianfoshan HospitalOTHER | 0 | Jan 5, 2024 | clinicaltrials |
| NCT05132790 | Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment | active not recruiting | N/A | 24 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06165900 | Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | recruiting | Phase 2 | 136 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06185569 | FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy(FREDO-ODX-23) | recruiting | — | 4,500 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04050228 | Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer | recruiting | N/A | 240 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT01872975 | Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery | active not recruiting | N/A | 1,636 | NSABP Foundation IncNETWORK | 7 | Dec 27, 2023 | clinicaltrials |
| NCT06175078 | Three-Dimensional Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses | not yet recruiting | — | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06001086 | A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05689619 | SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)(SILMET) | recruiting | N/A | 70 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04050423 | Investigation of Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses | recruiting | — | 1,200 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04134780 | Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response | recruiting | — | 150 | Sunnybrook Health Sciences CentreOTHER | 2 | Dec 14, 2023 | clinicaltrials |
| NCT04428528 | Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy | recruiting | — | 100 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00437879 | Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment. | recruiting | — | 600 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06154590 | Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor(NASBP-B-09) | not yet recruiting | — | 100 | DR. DIANE CHISESI NFS. MD. PHD.OTHER | 1 | Dec 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2024source: clinicaltrials